Curetis NV’s proposed private placement, intended to raise up to €18.4 million, has attracted less than half this amount, or €8.9 million, from investors. As a result, the molecular diagnostics company said it plans to reassess its strategic priorities.
This will entail re-evaluating funding for the commercialisation of Unyvero, a cartridge-based diagnostic for detecting pathogens and antimicrobial resistance markers in infectious disease indications; its European commercialisation activities, working capital requirements and research and development programmes.